Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, today said it has entered into a long-term agreement with Germany's Pieris AG for worldwide development and commercialisation of a protein molecule, primarily focused on ophthalmology.
Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, today said it has entered into a long-term agreement with Germany's Pieris AG for worldwide development and commercialisation of a protein molecule, primarily focused on ophthalmology.
Under the terms of the agreement, Pieris will take care of early stages of development in each collaborative programme using a novel Anticalin-based protein, while Stelis will be responsible for advancing the molecule through a first-in-human clinical study and drug manufacturing, the company said in a statement.
"The alliance deploys the synergies of Pieris' innovative drug discovery and early development capabilities with Stelis' strong bio-manufacturing and clinical development expertise," it said.
Following positive clinical data, the parties will co-develop programmes under a joint venture, the statement added.
Commenting on the development, Stelis CEO Anand Iyer said: "Our alliance with Pieris demonstrates how Stelis' strategic investments into state-of-the-art manufacturing facilities are attracting partners with cutting-edge biologics such as Anticalins, which hold great promise in the ophthalmic space."
Anticalins are artificial proteins and are subject of many research programmes worldwide for its possible usage in diagnostic and therapeutic applications.
Pieris CEO Stephen Yoder said: "Our strategic relationship with Stelis provides access to bio-manufacturing capabilities of the highest standard, yet in a very cost-effective manner."
The announcement is another example of how Pieris is finding innovative structures and committed partners to advance several Anticalins to the clinic in areas of high unmet need, Yoder added.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR